S&P 500 slips on report Fed’s Waller leading race to replace Powell; tech shines
Investing.com -- Shares of Pharmasgp climbed 4.3% following the announcement of their fourth quarter financial results, which surpassed expectations with robust revenue growth and a positive outlook for FY2025. The company’s fourth quarter revenue reached €30.2 million, marking a 19% increase year-on-year (YoY) and outperforming forecasts by 13%.
The growth was primarily attributed to the performance of Health Brands, which constitute 97% of Pharmasgp’s total revenue and experienced a 19% rise. Beauty Brands, although a smaller segment at 3% of revenue, also surpassed expectations with a 12% growth.
EBITDA for the quarter was reported at €10.2 million, which was 7% higher than anticipated, despite a margin that was roughly 200 basis points below expectations. It is important to note that consensus estimates for the company are not available.
Looking ahead, Pharmasgp has provided guidance for FY2025 with revenue projections ranging from €122 million to €128 million and EBITDA estimates between €37 million and €39 million, translating to a margin of 28.9-32%. These figures align with current forecasts, which predict revenues of €123.4 million and EBITDA of €39 million.
However, the company has a history of revising its guidance upward throughout the year, suggesting potential for future increases.
Analysts from RBC commented on the results, stating, "We see a reasonable likelihood that the company increases guidance through the year, in line with recent history. We expect these results to be taken well by investors."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.